Data is exponentially increasing while habits remain steeped in legacy systems and the past when it comes to safety and pharmacovigilance (PV) in the pharmaceutical ecosystem. Old processes and a historic approach cannot meet future requirements. Growing concerns, such as unstructured data and the emergence of patients as consumers, reveal themselves on a daily basis as new products are brought to market and new regulations come forth. The explosion of social media and immediate patient feedback won’t allow for slow, incremental improvements using current process-excellence methods. These problems require a revolutionary approach. A proactive approach and clear perspective around a product’s human impact are both relevant and necessary in providing insight into the future of drug safety. The rapidly changing landscape and volume of data flowing into pharmaceutical organizations requires real transformation. As such, human-centered design might just be the answer to creating a safer world.
Big Data, Bigger Challenge
Within pharma’s Big Data struggle is the challenge of balancing patient safety with the needs of caregivers, practitioners, manufacturers, and regulatory agencies. The only way to accomplish such a monumental balancing act is with a holistic view of the lifecycle of a compound or device – from discovery through patient experience. This view can be achieved only by understanding people’s needs using in-depth behavioral research – the backbone of human-centered design. Using the insights from research, human-centered design practitioners use the principles of simplicity and empathy to align data, people, process, technology, and environment. With the resulting holistic understanding of a compound or device lifecycle, a strategic direction may be realized.
Big Data for pharma can be broken into two major categories: structured clinical or research data (i.e., databases of regimented and well-monitored research), and unstructured, real-world data (i.e., from assays, electronic medical records and medical literature). Currently, structured clinical data is well managed individually, but aggregating these sources to look at the big picture is hindered by lengthy time frames for the translation between systems.
Recent advances in technology hint at the ability to automate activities like data translation across databases. Combined with other advances in globalized standards and guidelines, such as IDMP, data can be refined into a more useable format for collating and categorizing information. However, automated data curation and classification are in their infancy. While automation should reduce the timelines for these activities and move the industry to a more proactive approach to drug safety, these technologies are years away from being a complete solution. So, how do companies improve the current big-data landscape while planning for the possibility of technological advances?
The answer lies within human-centered design.
Regarding unstructured data, the problem lies in data access and the time-consuming hand coding for analysis. There are opportunities for improvement in addressing these sources using existing technologies that companies don’t currently leverage. Human-centered design can help companies determine how to best leverage current technology, such as Apple’s ResearchKit and CareKit, to make adverse event reporting easier and more feasible. Increasing the likelihood of reporting an adverse event through the use of personal technology devices increases the amount of data PV specialists have for decision making. This ultimately increases the likelihood of detecting potential adverse reactions. Coupled with additional data from wearable devices, like FitBit and Apple Watch, signal detection stands to benefit from robust contextual information. Dealing with all of the data from such a rich resource is another concern that human-centered design can help solve.
Just as the emerging technologies in the automation of database translation are on the horizon, so too are the technologies that can process the wealth of unstructured health data. As these technologies are implemented, it will be important for companies to prepare for the fundamental organizational shifts the technologies will undoubtedly create. Human-centered design will produce a roadmap for the future.
Why Human-Centered Design?
The incremental improvement model employed by many companies will not be enough to bring the pharmaceutical industry up to speed with Big Data. In the near future, the industry will need an overhaul and complete redesign of its data curation, monitoring, and analysis practices. Human-centered design has a multifaceted role in the strategic implementation of solutions for Big Data in pharmaceuticals. At the outset, human-centered design aligns stakeholders, business leaders, and operational leaders with common goals and a common approach to solutions. This includes the definition of roles and responsibilities for all involved in a collaborative, iterative environment.
With goals and responsibilities set, human-centered designers seek to understand the audience and craft messaging according to how people recognize and understand information. Whether through face-to-face conversations or email campaigns, behavioral scientists and designers can support the communication of strategic opportunities and plans to ensure a smooth transition and adoption.
Understanding the current state of the situation is essential to crafting a plan for change. Design professionals, specifically those using a human-centered methodology, craft visual representations that communicate the current state of the Big-Data problem, identifying pain points, bottlenecks, and areas of risk for the company. Understanding what works and what doesn’t in the current state is essential to facilitating data sharing across the company. Building this understanding also highlights the technology, data and human infrastructure of the company, confirming a solid foundation or providing recommendations for creating one.
Once foundational elements and current processes are mapped and well understood, the design of the future begins. Human-centered design combines research and insights with business and technology requirements to produce a future state that encompasses the vision laid out by stakeholders. In general, the future of Big-Data analytics in pharmaceuticals needs to take into account a broader set of inputs, like EMRs (electronic medical records). The challenges brought by these new sources will need to be incorporated into the design to ensure their benefits can be realized. Consideration of a broader audience such as practitioners, patients, and regulatory offices will also be required. These new audiences require different levels of information at different depths.
No Time to Waste
The rate at which data is produced is accelerating exponentially. Today, the amount of medical data doubles every 18 months. By the year 2020, it is expected that the amount of medical data will double every three months. Human-centered design can help uncover solutions applied in other sectors that will translate well to pharmaceutical organizations, highlighting commonalities among methods across verticals. Predictive analytics and forecasting models could provide valuable insight into potential situations for adverse events to be monitored more closely. These types of methods get the pharmaceutical industry one step closer to the proactive model of patient safety while taking into account the impact on people working within the system.
This article was originally published on www.lifescienceleader.com can be viewed in full


Archive
- October 2024(44)
- September 2024(94)
- August 2024(100)
- July 2024(99)
- June 2024(126)
- May 2024(155)
- April 2024(123)
- March 2024(112)
- February 2024(109)
- January 2024(95)
- December 2023(56)
- November 2023(86)
- October 2023(97)
- September 2023(89)
- August 2023(101)
- July 2023(104)
- June 2023(113)
- May 2023(103)
- April 2023(93)
- March 2023(129)
- February 2023(77)
- January 2023(91)
- December 2022(90)
- November 2022(125)
- October 2022(117)
- September 2022(137)
- August 2022(119)
- July 2022(99)
- June 2022(128)
- May 2022(112)
- April 2022(108)
- March 2022(121)
- February 2022(93)
- January 2022(110)
- December 2021(92)
- November 2021(107)
- October 2021(101)
- September 2021(81)
- August 2021(74)
- July 2021(78)
- June 2021(92)
- May 2021(67)
- April 2021(79)
- March 2021(79)
- February 2021(58)
- January 2021(55)
- December 2020(56)
- November 2020(59)
- October 2020(78)
- September 2020(72)
- August 2020(64)
- July 2020(71)
- June 2020(74)
- May 2020(50)
- April 2020(71)
- March 2020(71)
- February 2020(58)
- January 2020(62)
- December 2019(57)
- November 2019(64)
- October 2019(25)
- September 2019(24)
- August 2019(14)
- July 2019(23)
- June 2019(54)
- May 2019(82)
- April 2019(76)
- March 2019(71)
- February 2019(67)
- January 2019(75)
- December 2018(44)
- November 2018(47)
- October 2018(74)
- September 2018(54)
- August 2018(61)
- July 2018(72)
- June 2018(62)
- May 2018(62)
- April 2018(73)
- March 2018(76)
- February 2018(8)
- January 2018(7)
- December 2017(6)
- November 2017(8)
- October 2017(3)
- September 2017(4)
- August 2017(4)
- July 2017(2)
- June 2017(5)
- May 2017(6)
- April 2017(11)
- March 2017(8)
- February 2017(16)
- January 2017(10)
- December 2016(12)
- November 2016(20)
- October 2016(7)
- September 2016(102)
- August 2016(168)
- July 2016(141)
- June 2016(149)
- May 2016(117)
- April 2016(59)
- March 2016(85)
- February 2016(153)
- December 2015(150)